REZOLVE-AD: Monthly and Quarterly Dosing of Rezpegaldesleukin Effective for AD
Key Takeaways
According to a Nektar Therpeutics announcement, rezpegaldesleukin demonstrated durable and deepening efficacy through 52 weeks in patients with moderate-to-severe atopic dermatitis (AD).
Monthly (Q4W) and quarterly (Q12W) maintenance dosing sustained high response rates across EASI, vIGA-AD, and itch endpoints.
Increases in complete skin clearance (EASI-100) were observed over time, and a favorable safety profile was reported.
Results from the blinded 36-week maintenance period showed rezpegaldesleukin demonstrated sustained disease control and new or deepening efficacy in moderate-to-severe atopic dermatitis (AD) with both monthly and quarterly dosing regimens, according to an announcement from the manufacturer.
The 52-week maintenance data from the phase 2b REZOLVE-AD trial evaluating rezpegaldesleukin, a first-in-class regulatory T-cell (Treg) biologic, in patients with moderate-to-severe AD came from a study population of 393 adults with moderate-to-severe AD. Participants followed a 16-week induction period. Those receiving rezpegaldesleukin who also achieved at least a 50% improvement in Eczema Area and Severity Index (EASI-50) were re-randomized to continue the same dose administered every 4 weeks (Q4W) or every 12 weeks (Q12W) through week 52. Maintenance efficacy was assessed across multiple disease measures (EASI-75, EASI-90, EASI-100, vIGA-AD 0/1, and Itch NRS).
The results showed that among patients receiving the 24 µg/kg dose, 71% (Q4W) and 83% (Q12W) maintained EASI-75 responses at week 52, while 85% and 63%, respectively, maintained vIGA-AD 0/1 responses. The responses were also observed across dosing schedules. A significant proportion of patients achieved new responses during maintenance, including higher-level endpoints, the manufacturer noted. Complete skin clearance increased substantially over time. EASI-100 response rates increased from 4% to 22% among all re-randomized patients, with Q4W dosing and from 9% to 18% with Q12W dosing between weeks 16 and 52. Researchers reported larger improvements among patients entering maintenance with higher baseline responses.
"These data show that rezpegaldesleukin, as a broad-based Treg agonist, is emerging as one of the most important mechanisms in development to treat atopic dermatitis," said Jonathan Silverberg, MD, PhD, MPH, Professor of Dermatology at The George Washington University School of Medicine and Health Sciences in Washington, DC, in the press release. "With both monthly and quarterly maintenance dosing, new and sustained responses were observed across the key endpoints of EASI-75, vIGA-0/1 and itch and with a large proportion of patients achieving complete clearance with EASI-100."
Source: Nektar Therapeutics press release. Feburary 10, 2026.